IPO Boutique

TetraLogic Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on TetraLogic Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
TetraLogic PharmaceuticalsTLOG -
NASDAQ
$7.00-$7.00 $7.00 $7.007.2 million12/12/2013
Oppenheimer & Co., Guggenheim Securities, Needham & Co.
Co-Manager(s):
Health Care
Filing(s):

Filed 2013-10-18



TetraLogic Pharmaceuticals Quote & Chart - Click for current quote - TLOG

About TetraLogic Pharmaceuticals (adapted from TetraLogic Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct.

This description is adapted from TetraLogic TLOG prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as TetraLogic TLOG "TLOG" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved